FinTech Dev and Data
Stock Risk Measures for Enanta Pharmaceuticals Inc
A quantitative factor review, as of July 31, 2020.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: August 02, 2020
See how we arrive at an overall risk score of
for ENTA below.
ENTA Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Enanta Pharmaceuticals Inc. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how ENTA stock compares to 2,000+ US-based stocks, and to
peers in the Health Technology sector and Biotechnology industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
- Symbol: ENTA
- FactorPad FPID: f32qzh
- SEC CIK: 0001177648
- Share Class FIGI: BBG001V9NSC3
- Location: Watertown, MA US
- Web: http://www.enanta.com
- Employees: 132
Sector and Industry
- Sector: Health Technology
- Industry: Biotechnology
- SIC Code: 2834
Shares and Float
- Shares Outstanding: 20,004,300
- Shares Trading: 17,652,775
- Percent Trading: 88.2 %
Earnings and Dividends
- Trailing 12-month earnings: 1.2
- Next earnings date: 2020-08-04
- Dividends in last 12 months: None
- Ex-dividend date: None
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 0.88 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $917,197,155 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $7,734,999 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): -38.41% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): 2.63% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
ENTA stock risk
ENANTA PHARMACEUTICALS INC stock beta
ENTA risk report
ENTA risk analysis
ENANTA PHARMACEUTICALS INC credit risk
ENTA liquidity risk
ENTA systematic risk
ENTA specific risk
ENANTA PHARMACEUTICALS INC volatility
ENTA financial ratio